Novo Nordisk and Life Edit Therapeutics establish multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseasesGlobeNewsWire • 05/24/23
Novo Nordisk: Flourishing Financials And Emerging Opportunities In Diabetes And ObesitySeeking Alpha • 05/23/23
Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trialGlobeNewsWire • 05/22/23
Prescription-drug costs in spotlight as pharmacy benefit reform advances in SenateMarket Watch • 05/11/23
Novo Nordisk A/S purchases B shares worth DKK 3,889 million from Novo Holdings A/S under the 2023 share repurchase programmeGlobeNewsWire • 05/09/23